The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1444
Extended-Release Hydrocodone (Zohydro ER) for Pain
The full article is available to subscribers Subscriber Login   

The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone (Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which alternative treatment options are inadequate. Zohydro ER is the first single-ingredient hydrocodone product to be marketed in the US. Hydrocodone has been available for years in combination with acetaminophen (Vicodin, and others) or ibuprofen (Vicoprofen, and others).1

PHARMACOLOGY — Hydrocodone is a semisynthetic opioid. It is metabolized primarily by CYP3A4-mediated N-demethylation to norhydrocodone and to a lesser extent by CYP2D6-mediated O-demethylation to hydromorphone. Overall hydrocodone exposure is similar after administration of Zohydro ER or comparable daily doses of immediate-release hydrocodone combination products, but ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Extended-Release Hydrocodone (Zohydro ER) for Pain
Article code: 1444b
 Electronic, downloadable article - $25